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Abstract  
Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), 
typically present at an advanced stage. The current treatment landscape, which includes 
chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly 
evolving, including for patients with SqCLC. Prompt molecular and immune biomarker 
testing can serve to guide optimal treatment choices, and immune biomarker testing is 
becoming more important for this patient population. This review provides an overview of 
current and emerging practices and technologies for molecular and immune biomarker testing 
in advanced non–small-cell lung cancer, with a focus on SqCLC.  
Keywords: Non–small-cell lung cancer; Squamous-cell lung cancer; Molecular testing; PD-
L1; Pathology; Immune-oncology; Biomarker; Targeted treatment  
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Introduction 
Over the past decade, determining the histology of non–small-cell lung cancer (NSCLC) has 
become standard as treatment options vary by tumor histologic subtype. Multiple guidelines, 
including the National Comprehensive Cancer Network (NCCN), European Society for 
Medical Oncology (ESMO), and the College of American Pathologists (CAP)/International 
Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology 
(AMP) guidelines, provide recommendations for performing molecular testing to further 
guide treatment with targeted therapies in advanced NSCLC, including squamous-cell lung 
cancer (SqCLC).1-3 Immune testing, performed by immunohistochemistry (IHC), for 
expression of programmed death-ligand 1 (PD-L1) as a predictive marker of response to anti–
programmed death-1 (PD-1)/–PD-L1 checkpoint inhibitors is also now being incorporated 
into many guidelines.2, 3  
The majority of patients (68-79%) with lung cancer present at an advanced stage,4-7 and 
often, only small biopsy or cytology samples are available for diagnosis.7, 8 Therefore, it is 
important to prioritize biopsy tissue from NSCLC tumors to allow for use in both pathologic 
diagnosis and molecular and immune biomarker testing to help guide individualized 
treatment decisions. Herein, we review the current evidence and practice for pathologic 
diagnosis and molecular and immune biomarker testing in NSCLC, with a focus on SqCLC, 
and we evaluate how changes in the treatment and technological landscape are likely to 
impact molecular and immune biomarker testing in SqCLC within the next 5 years and the 
challenges that must be overcome.  
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Current Practice for Pathologic Diagnosis and Molecular and Immune Biomarker Testing 
in NSCLC, including SqCLC 
As distinguishing between the different NSCLC subtypes has become central to patient 
management due to their therapeutic implications, it is recommended that samples showing 
NSCLC be subject to pathologic diagnosis with histologic subtyping.9 Furthermore, current 
best practice involves a multidisciplinary team approach to coordinate tumor tissue 
optimization for both pathologic diagnosis and molecular testing to accelerate diagnostic 
molecular and immune biomarker testing results and to ensure that the most appropriate 
treatment choice is recommended to the patient in an expeditious fashion7 (Figure 1). 
The pathologic diagnosis of NSCLC subtypes, which include SqCLC, adenocarcinoma, and 
large-cell carcinoma, is a multistep process.9 In most cases, the classic histologic features of 
tumor cells from SqCLC and other subtypes can be readily distinguished by evaluating tissue 
sections stained with hematoxylin and eosin.7, 9 In the roughly 20-40% of challenging cases in 
which the NSCLC subtype cannot be determined by histology alone,10, 11 limited IHC on 
tissue sections to specifically detect p40/p63, thyroid transcription factor-1 (TTF-1), and in a 
few cases, neuroendocrine biomarkers such as neuron-specific enolase and chromogranin A 
can be used to differentiate between SqCLC, adenocarcinoma, and large- and small-cell 
carcinoma, respectively.7, 12-16 P40 is a more specific and sensitive marker for SqCLC than 
p63 (p40: sensitivity 100%, specificity 98%; p63: sensitivity > 90%, specificity about 60-
75%), while the TTF-1 marker has > 80% sensitivity and 97% specificity for 
adenocarcinoma.9, 12, 13, 17, 18 Cytokeratin 7 is preferentially expressed in adenocarcinoma19 
and can be used as a biomarker to support the diagnosis of adenocarcinoma, but only when 
used alongside other markers since it is not specific for adenocarcinoma. 
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Looking specifically at SqCLC, routine molecular testing for alterations such as epidermal 
growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene 
rearrangements, and ROS proto-oncogene 1 (ROS-1) gene fusions is not recommended due to 
their very low incidences in SqCLC (< 4% , < 3%, and 0%, respectively).20-27 However, 
molecular testing for these alterations should be considered for patients with SqCLC who are 
younger, who have never smoked or are former very light smokers (i.e., < 15 packs per 
years), or for patients with small biopsy samples or mixed histology,1-3 and potentially for 
patients who are of Asian ethnicity, although the latter characteristic is not included in current 
guidelines. The NCCN and CAP/IASLC/AMP guidelines also advise performing broad 
molecular testing beyond EGFR mutations and ALK and ROS-1 gene alterations to assist in 
the identification of rare genomic drivers for which effective therapy may already be 
available (e.g., translocations of the rearranged during transfection [RET] gene and 
mesenchymal-epithelial transition exon 14 mutations) and to counsel patients regarding 
available clinical trials.1, 3 With the recent approval of dabrafenib plus trametinib for the 
treatment of patients with NSCLC whose tumors carry the proto-oncogene BRAF V600E 
mutation,28 testing for this mutation could also be considered for SqCLC.3 However, the 
mutation is rare in SqCLC and routine testing is therefore not recommended.29, 30 Thus, 
currently, the vast majority of testing performed on SqCLC biopsy samples consists of 
p40/p63 immunostaining on tissue sections to confirm the histologic subtype and PD-L1 
assessment to determine eligibility for checkpoint inhibition front-line. 
The turnaround time for obtaining the results of molecular testing is an important concern, as 
patients with advanced disease benefit from starting appropriate treatment as soon as 
possible. The CAP/IASLC/AMP guidelines for clinical practice recommend a maximum of 
2 weeks for the completion of all molecular testing.1 A streamlined process that incorporates 
a multidisciplinary team is pivotal for meeting the benchmark turnaround time for the 
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completion of all molecular tests31 (Figure 1). This process should include optimizing 
procedures and workflows, such as the transfer of tumor specimens between thoracic 
surgeons, interventional pulmonologists, radiologists, and pathologists and intra-laboratory 
communication. Recently, a study that analyzed routine nationwide molecular testing in 
France observed that obtaining results from molecular testing that approached acceptable 
turnaround times was feasible (median of 11 days from initiation of analysis to report of 
results).32  
The type of assays used is also important, for which the CAP/IASLC/AMP guidelines further 
recommend that each laboratory determine the minimum proportion and number of cancer 
cells needed to detect a mutation during validation of an assay.1 These guidelines were last 
published in 2013, and updated guidelines with evidence-based expert consensus opinion will 
be published soon.  
Lastly, it is important to consider potential differences in the implementation of molecular 
testing for NSCLC, including SqCLC, which may affect successful adoption into practice. 
These differences may arise partly due to regional availability of tests, reimbursement 
policies, and treatment settings (e.g., community vs. academic centers).32-34 Greater 
uniformity in the practical implementation of molecular testing for NSCLC may be achieved 
through the development of inter- and intra-institutional and network pathways.32  
Technologies for Molecular Testing in NSCLC – Current and New Methods 
In practice, the use of multiplex or next-generation sequencing (NGS) platforms for 
molecular testing is often restricted to larger academic centers; many community treatment 
settings still rely on single-gene testing or sending samples out to commercial laboratories for 
testing. For molecular testing of EGFR mutations in NSCLC, guidelines recommend the use 
of any validated methodology with adequate coverage of mutations in exons 18-21, including 
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mutations associated with specific drug resistance.1-3, 35 The standard testing methodology for 
ALK gene rearrangements and ROS-1 gene fusions is fluorescence in situ hybridization 
(FISH), but IHC with high-performance ALK antibodies is also an approved ALK assay used 
for treatment decisions.1-3, 35, 36  
As additional therapeutic targets are identified and new treatments are approved for patients 
with SqCLC, moving toward prioritizing tissue preservation for molecular testing as standard 
procedure will become a major practical change for institutions and physicians who manage 
patients with this NSCLC subtype. The implementation of newer technologies, such as NGS, 
may assist in addressing the challenges associated with an increased need for performing 
molecular testing on small biopsy samples in SqCLC and improve turnaround times for 
molecular testing (Table 1). The current reality is, however, that the lack of genomic targets 
and approved therapies in SqCLC means that relatively few cases are subjected to molecular 
screening. Hence, tissue availability for PD-L1 IHC, for example, is therefore less 
challenging than for adenocarcinoma. 
NGS. NGS technologies are high-throughput methods that allow for the parallel sequencing 
of multiple targeted genomic regions and include whole genome or exome capture 
sequencing (deoxyribonucleic acid-based sequencing platform), whole or targeted 
transcriptome sequencing (ribonucleic acid-based sequencing platform), and epigenetic 
profiling37 (Table 1). The potential for increased clinical use of NGS is supported by the 
recent validation of an NGS-based framework as the primary molecular testing method in a 
large, prospective clinical trial with patients with advanced NSCLC.38 As approved targeted 
treatments are limited for patients with SqCLC, routine molecular testing using NGS is not 
currently required. However, the use of NGS has facilitated the screening of patients for 
enrollment in ongoing clinical trials aimed at identifying new actionable molecular targets 
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and evaluating novel targeted therapies that may benefit this patient population.39-42 NGS was 
also recently used in a study that showed that patients who had ErbB–mutation-positive 
SqCLC had higher progression-free survival (PFS) and overall survival when treated with 
afatinib than when treated with erlotinib, or with patients who had ErbB–mutation-negative 
disease.43 These findings, in addition to the recent U.S. Food and Drug Administration (FDA) 
approval of an NGS-based companion test to identify patients with NSCLC eligible for 
treatment with crizotinib, gefitinib, and dabrafenib combined with trametinib, 44 support the 
clinical application of NGS for molecular testing in NSCLC, including SqCLC. 
Furthermore, use of NGS for molecular testing in NSCLC may become routine with the 
potential role of tumor mutational burden (TMB) to assess the likelihood of benefit from 
immunotherapy. In a study that included 2 independent cohorts, patients with NSCLC whose 
tumors had a high TMB, or nonsynonymous mutation burden, experienced greater clinical 
benefit from treatment with the PD-1 inhibitor pembrolizumab than patients whose tumors 
had a lower mutation load.45 More recently, results from a subset analysis of a phase III 
clinical trial showed that patients with NSCLC whose tumors had a high TMB and PD-L1 
expression by IHC had a higher clinical response to first-line treatment with the PD-1 
inhibitor nivolumab than with chemotherapy.46  
Despite the applicability of NGS for molecular testing in NSCLC, and potentially for SqCLC 
as more targeted treatments become available, several drawbacks need to be addressed before 
it is routinely implemented in clinical practice. The implementation of NGS into regulatory 
and standard diagnostic pathways may be negatively affected by the multiple proprietary 
NGS variant databases,47 the use of different methodologies (e.g., sequencing of non-
amplified genome vs. amplicons),48 the inconsistent concordance between different biopsy 
types such as liquid biopsies and matched tissue biopsies, and the very large volume of 
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complex bioinformatics data that require analysis.49 Another potential drawback of NGS is 
the lack of uniform policy for supporting, covering, or reimbursing the use of NGS 
comprehensive molecular testing, presenting additional challenges to its implementation in 
clinical practice.34, 47 Furthermore, many of the NGS platforms currently used in the clinical 
setting are amplicon-based, which do not detect gene fusions or gene rearrangements, unlike 
newer platforms such as Archer® (ArcherDX, Inc., Boulder, CO), FoundationOne® 
(Foundation Medicine, Cambridge, MA), and NovaSeq® (Illumina, Eindhoven, The 
Netherlands). Lastly, the limited information currently available on the applicability of NGS 
for biomarker testing relating to immunotherapies will further affect its adoption for 
molecular testing for SqCLC.  
Analysis of Circulating-Tumor DNA (Liquid Biopsies). Liquid biopsies are performed on 
blood samples and can be used to assess circulating-tumor cells, circulating-tumor DNA, 
circulating cell-free DNA, and exosomes for tumor-associated genetic and molecular 
alterations through several approaches.50, 51 The use of blood samples for liquid biopsies 
offers several potential advantages over tissue biopsy testing, including quick and non-
invasive sample retrieval, faster testing turnaround times, and the potential for monitoring 
responses and resistance to treatment.50, 51 Furthermore, NSCLC tumors are highly 
heterogeneous and the ability to assess circulating-tumor cells, circulating-tumor DNA, 
circulating cell-free DNA, and exosomes that derive from a patient’s whole tumor or tumors 
allows for the detection of intra- and inter-tumor heterogeneity.22, 50-53 In 2016, the FDA 
approved a companion diagnostic test for the detection of exon 19 deletions or exon 21 
substitution mutations in EGFR from liquid biopsies to identify patients with NSCLC who 
were eligible for treatment with erlotinib.54 The indication for the companion test was 
subsequently extended to include the detection of EGFR T790M mutations from liquid 
biopsies to identify tyrosine kinase inhibitor-resistant patients eligible for treatment with 
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osimertinib.55 Despite recent advances, however, the remaining technical challenges, 
including inconsistent concordance compared with tissue,50, 51, 56 will need to be overcome 
prior to the implementation of liquid biopsies into practice (Table 1).  
Overall, a number of new technologies are becoming available for molecular testing and may 
assist in addressing some of the issues that will arise from an increased need for molecular 
testing in SqCLC in the near future. Validating these methodologies and using external 
quality assurance programs will be essential to ensuring accurate and timely results to guide 
treatment for patients.  
Impact of New Treatments on Molecular and Immune Testing in qCLC 
Targeting genetic abnormalities in SqCLC remains a research aim; however, the molecular 
profile of SqCLC is complex and SqCLC tumors have a high mutation load.22 Consequently, 
the profile of SqCLC is unlikely to offer many actionable molecular targets, as the dominant 
molecular changes are not addictive oncogenes.22 Indeed, this lack of identifiable oncogenic 
drivers in SqCLC has proven to be a challenge, and targeting single genetic alterations seems 
to achieve only modest clinical benefits in advanced SqCLC.57-62  
Conversely, the elucidation of how tumor cells employ various complex and overlapping 
mechanisms to evade the immune system63 has led to an increased focus on immuno-
oncology, particularly the PD-1/PD-L1 axis. Immunotherapy with anti–PD-1/–PD-L1 
antibodies now provides an important alternative to chemotherapy for SqCLC.64-67 The 
emergence of immunotherapy for the treatment of patients with advanced SqCLC has been 
transformative and will further impact the future of molecular and immune testing by leading 
to changes in the way genomic alterations are explored in SqCLC. 
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Given the challenges in developing targeted therapies for advanced SqCLC previously noted, 
novel study designs have been developed to evaluate additional potential targeted treatments 
for advanced SqCLC and, most recently, non-squamous NSCLC. For example, the Lung 
Cancer Master Protocol (Lung-MAP) study (SWOG S1400) seeks to identify potentially 
actionable molecular alterations in the second-line advanced SqCLC setting through the 
comprehensive screening of patients via an NGS platform.39, 68 The NGS platform used in 
Lung-MAP detects base substitutions, short insertions and deletions, copy number alterations, 
and gene fusions across 287 cancer-related genes (Foundation Medicine, Cambridge, MA).69 
The rapid turnaround of results from the NGS screening (i.e., 10 to 14 days), which is critical 
for patients with advanced SqCLC, may be partly responsible for enabling patients to be 
prescreened with molecular testing prior to disease progression during or after first-line 
therapy, thus facilitating the efficient assignment of eligible patients to a sub-study based on 
the identification of biomarkers or to a non-match sub-study in which they receive 
immunotherapy. The testing approach of the Lung-MAP study may affect how new targeted 
agents are developed for SqCLC and non-squamous NSCLC and, consequently, may 
influence the implementation of additional molecular testing in practice. 
Recently, 3 Lung-MAP phase II sub-studies that included the fibroblast growth factor 
receptor inhibitor AZD4547, the cyclin-dependent kinase 4/6 inhibitor palbociclib, and the 
phosphoinositide 3-kinase inhibitor taselisib failed to meet their primary end points in their 
respective biomarker-enriched cohorts of patients with SqCLC.70-72 Nonetheless, the sub-
studies served to catalog the array of diverse mutations present in these cancer-related genes 
among patients with SqCLC. On a rolling basis, new Lung-MAP sub-studies continue to be 
incorporated as new targeted therapies with actionable molecular targets become available.  
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Immune Biomarker Testing for Immunotherapy Treatments 
Immune testing for checkpoint inhibitor PD-L1 protein expression as a predictive biomarker 
for response to anti–PD-1 or anti–PD-L1 antibodies is evolving. Testing for PD-L1 protein 
expression is performed by IHC, with each approved anti–PD-1/–PD-L1 immunotherapy 
having a different companion/complementary PD-L1 IHC assay.73-78  
The anti–PD-1 agent pembrolizumab is approved for first-line treatment of patients with 
advanced NSCLC, including SqCLC, in patients with high PD-L1 expression (tumor 
proportion score ≥ 50%),67, 75, 76 based on a phase III, prospective, randomized clinical study 
showing superior efficacy and lower toxicity for pembrolizumab than for chemotherapy.67 
Furthermore, second-line treatment of patients with advanced NSCLC with anti–PD-1 agents 
pembrolizumab and nivolumab and anti–PD-L1 agent atezolizumab have all demonstrated 
superiority to docetaxel chemotherapy after initial platinum doublet chemotherapy in 
randomized phase III studies.64-66 The studies with nivolumab and atezolizumab included 
patients with any or no PD-L1 expression, while the study with pembrolizumab included only 
patients with a tumor proportion score of > 1%. However, the benefit of immunotherapy over 
chemotherapy increased with higher PD-L1 expression in each of these trials. Thus, PD-L1 
testing at diagnosis for metastatic disease has been incorporated into guidelines such as the 
NCCN guidelines.3 The recently updated American Society of Clinical Oncology treatment 
guidelines state that the guidance starts from the point at which the results of molecular and 
PD-L1 testing are known; however, reviewing the molecular testing literature is beyond the 
scope of the guideline.79 
The existence of multiple distinct diagnostic assays for determining PD-L1 expression to 
guide treatment with each anti–PD-1/–PD-L1 antibody constitutes a barrier to routine 
implementation of PD-L1 testing in clinical practice due to the impracticality of conducting 
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multiple assays for the same protein. Consequently, there is great interest in establishing 
whether these assays provide comparable results for PD-L1 expression and could be used 
interchangeably in laboratories. Recently, comparison studies between the multiple PD-L1 
assays reported a high degree of agreement between most assays.80-82 However, interchanging 
the assays and PD-L1 expression cut-off values used for the different anti–PD-1/–PD-L1 
antibodies led to a misclassified PD-L1 status for some patients, highlighting the need for 
standardization.81 Validated cut-offs are a function of drug activity and should remain allied 
to the drug/indication relevant to the patient and not allied to the assay. 
A further need for standardization of PD-L1 testing relates to the reporting of PD-L1 
expression by pathologists. Identifying the subset of patients with NSCLC who will benefit 
the most from therapy with anti–PD-1/–PD-L1 antibodies can be challenging, given the 
diversity of PD-L1 expression levels used to stratify patients in clinical studies for different 
anti–PD-1/–PD-L1 antibodies.46, 65, 67 Therefore, standardized pathology reporting for PD-L1 
expression using a numeric value rather than stating PD-L1 positivity/negativity is mandatory 
for the treating oncologist.  
More recently, a randomized phase II trial comparing pemetrexed and carboplatin plus 
pembrolizumab to pemetrexed and carboplatin in patients with non-squamous NSCLC 
showed superior results with respect to response rate and PFS for the combination with 
pembrolizumab.83 Although the number of patients involved was small, there was some 
evidence that more patients with a PD-L1 tumor proportion score of ≥ 50% achieved an 
objective response with pembrolizumab plus chemotherapy (80%; n = 16) compared with 
patients with a tumor proportion score of 1-49% (26%; n = 5). While this study did not 
include patients with SqCLC, several randomized phase III trials in the first-line setting 
comparing treatment with anti–PD-1 and anti–PD-L1 checkpoint inhibitors alone or in 
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combination with anti-cytotoxic T–lymphocyte-associated protein 4 inhibitors and trials 
comparing chemotherapy alone or in combination with checkpoint inhibitors are currently 
ongoing. The results of these trials will undoubtedly determine the role of immune testing for 
PD-L1 protein expression at diagnosis, depending on where the role of first-line 
immunotherapy is challenged. In addition, a recent randomized phase III trial in patients with 
stage III NCSLC, including SqCLC, showed that standard chemotherapy/radiotherapy 
followed by durvalumab yielded superior PFS compared to chemotherapy/radiotherapy alone, 
irrespective of PD-L1 expression before chemotherapy/radiotherapy.84 Other trials with 
checkpoint inhibitors are ongoing in patients with stage III NSCLC and in the adjuvant 
setting in patients with earlier-stage disease. The results of these trials may influence how we 
test for PD-L1 expression in these stages, but for now, we suggest a pathway for this testing 
in Figure 2. 
Because PD-L1 protein expression is an imperfect biomarker, other potential biomarkers such 
as TMB are currently being evaluated in several ongoing studies. At present, assessment of 
TMB is not standardized and it is not part of routine management. However, recent 
retrospective studies showing that high TMB predicted favorable outcomes for checkpoint 
inhibitor therapy and that the combination of TMB with PD-L1 expression levels was 
superior to either marker alone45 support the implementation of TMB for use as a biomarker 
in the future.  
Discussion: The Future for Molecular and Immune Testing in SqCLC 
The molecular and immune testing landscape for SqCLC is likely to change rapidly over the 
next several years due to the emergence of immunotherapies such as anti–PD-L1 and anti–
PD-1 antibodies and novel targeted therapies for advanced SqCLC. Indeed, the need to test 
for PD-L1 expression levels before prescribing pembrolizumab as first-line therapy for 
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advanced NSCLC, including SqCLC, has already meant that institutions are beginning to 
implement this test as part of standard practice. In some instances, this is occurring 
“reflexively,” without requiring additional orders. Therefore, integration of new molecular 
and immune testing into standard diagnostic and treatment algorithms and guidelines for 
advanced SqCLC will become essential to ensuring that patients receive appropriate and 
timely treatment.  
Initially, the use of NGS for molecular testing in SqCLC is more likely to be adopted over 
other testing platforms due to features such as tumor tissue sample optimization, fast 
turnaround, and comprehensive genomic testing. The use of NGS testing may further expand 
as the significance of TMB as a biomarker for response to immunotherapy becomes better 
understood. However, analyses on value (in clinical trials) and the cost of increased screening 
and the use of comprehensive technology platforms that test for more than standard genetic 
alterations with approved targeted therapies will be necessary for these platforms to be 
widely accepted among payers and regulators. 
Lastly, as molecular testing for SqCLC evolves, greater education for patients will be needed. 
Improved patient communication will help patients understand the need for, timing of, 
eligibility for, and results from molecular tests and how these results may affect their 
treatment options. 
Conclusion 
The workload for pathologists will increase due to increased requests for genomic and 
proteomic profiles in SqCLC. The establishment of multidisciplinary teams and best practices 
for institutions to accommodate the need for, and to meet benchmark timelines for, molecular 
and immune biomarker testing for NSCLC, including, SqCLC, is recommended. 
Furthermore, as new therapeutic targets are identified for SqCLC, standardized pathology 
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reporting of new genomic and proteomic test results will play an important role in ensuring 
that accurate, concise, and appropriate information is available for clinicians to guide 
treatment decisions. 
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Table 1 Key Features of Single-Gene, Next-Generation Sequencing, and Liquid Biopsy Technologies in SqCLC39-42, 50, 51, 85  
Technology Single-Gene Testing Next-Generation Sequencing Liquid Biopsy 
Features • Targeted gene testing 
using Sanger DNA 
sequencing, RT-PCR, 
FISH, and IHC 
 
• High-throughput genetic 
profiling for decision-
making in individual 
patients 
• Includes whole genome or 
exome capture sequencing 
of DNA, whole or targeted 
transcriptome sequencing 
of RNA, and epigenetic 
profiling 
• Analysis of circulating 
cell-free DNA from 
plasma via quick and non-
invasive retrieval 
• Method for potentially 
monitoring responses and 
resistance to treatment 
 
Advantages for SqCLC • Current approach for 
decision-making in 
individual patients if it can 
be performed in the 
benchmark turnaround 
time for results 
• Allows for the sparing of 
limited SqCLC tumor 
tissue for testing 
• Expands testing beyond 
currently known 
biomarkers 
• Facilitates the screening of 
patients with SqCLC for 
enrollment in ongoing 
clinical trials aimed at 
identifying new actionable 
molecular targets 
• May allow for an initial 
diagnosis of patients who 
may not be able to 
undergo a biopsy due to 
advanced disease 
• Analyzes circulating-
tumor cells, circulating-
tumor DNA, circulating 
cell-free DNA, and 
exomes, which may help 
overcome sampling and 
tumor heterogeneity 
Limitations for SqCLC • Tissue samples are often 
inadequate for all required 
testing, requiring greater 
tissue prioritization 
• Multiple proprietary 
databases negatively 
impact implementation 
into regulatory and 
• Testing of circulating-
tumor cells is not yet 
optimized for use with 
next-generation 
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standard diagnostic 
pathways 
• Potential issues with 
reimbursement may affect 
implementation of 
comprehensive molecular 
testing into clinical 
practice 
• Most NGS platforms used 
in clinical institutions are 
amplicon-based, which do 
not detect gene fusions or 
rearrangements 
• Analysis of a large volume 
of bioinformatics 
• Limited information on its 
applicability for biomarker 
testing relating to 
immunotherapies 
sequencing and other less 
sensitive platforms 
• Technical challenges 
remain to validate and 
implement for use in 
clinical practice 
 
Abbreviations: DNA = deoxyribonucleic acid; FISH = fluorescent in situ hybridization; IHC = immunohistochemistry; NGS = next-generation 
sequencing; RNA = ribonucleic acid; RT-PCR = reverse transcription polymerase chain reaction; SqCLC = squamous-cell lung cancer. 
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Figure 1 Multidisciplinary Scheme and Best Practice Timelines for Each Clinical Stage 
Following the Patient’s Referral 
Abbreviations: ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor 
receptor; FISH = fluorescent in situ hybridization; IHC = immunohistochemistry; MDT = 
multidisciplinary team; PD-L1 = programmed death-ligand 1; ROS-1 = ROS proto-oncogene 
1. 
Figure 2 Recommended Molecular and Immune Biomarker Testing for Patients With 
Confirmed SqCLC Histology 
Abbreviations: ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor 
receptor; FISH = fluorescent in situ hybridization; IHC = immunohistochemistry; PD-L1 = 
programmed death-ligand 1; ROS-1 = ROS proto-oncogene 1; SqCLC = squamous-cell lung 
cancer.  
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responsible 
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referring clinician
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(tumor sample 
collection/fixation)
Fixation/tissue 
processing
Histology evaluation 
and pathologist’s 
review
Standard molecular and immune biomarker
testing (in parallel):
•    EGFR-mutation testing (exon 18-21
     sequencing)
•    ALK rearrangement (IHC+ and/or FISH+)
•    ROS-1 fusions (FISH+)
•    PD-L1 (companion/complementary IHC)
histology and molecular 
MDT
Medical oncologist
Pulmonologist
Radiation oncologist
Thoracic surgeon
Radiologist
Pathologist
Pulmonologist
Interventional radiologist
Thoracic surgeon 
Pathologist Pathologist
10 working days1-2 working days
(except IHC)
24 hours
MDT strategizes to optimize 
tumor sample collection and 
preservation
If adenocarcinoma/adenocarcinoma component, reflex 
decision by pathologist to proceed with molecular testing
For non-adenocarcinoma histology and patients who are 
younger (< 50 years), non-smokers or former light smokers, 
or of Asian ethnicity, decision discussed in MDT/pre-emptive 
request by MDT for molecular testing; reflex decision by
pathologist to proceed with PD-L1 immune testing
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